A method for constructing a mettl3 transgenic knockout mouse model
The Cre-LoxP recombinant system was used to construct a mouse model of pancreatic β-cell-specific knockout of Mettl3, which solved the problem of insufficient model construction in the existing technology, revealed the role of Mettl3 in mature pancreatic β-cells, provided a new target for diabetes treatment, and relieved endoplasmic reticulum stress and improved insulin synthesis and secretion by overexpressing Mettl3.
Patent Information
- Application Number
- CN202311654666.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-12-05
- Publication Date
- 2026-02-06
- Estimated Expiration
- 2043-12-05
AI Technical Summary
Current technologies have failed to effectively construct transgenic mouse models with specific knockout of Mettl3 in pancreatic β cells, which has affected research on the pathogenesis and treatment of diabetes.
Using the Cre-LoxP recombination system and the Cre mouse model driven by the Ins1 and Ins2 insulin promoters, two types of pancreatic β-cell-specific Mettl3 knockout mice, MKO-MIP and MKO-RIP, were constructed. Genotypes were identified by PCR, and glucose metabolism, morphology, and molecular biology experiments were conducted to explore the effects of Mettl3 on mature pancreatic β-cells.
A specific and efficient Mettl3 knockout mouse model was successfully constructed, revealing the function and molecular mechanism of Mettl3 in mature pancreatic β cells, providing a new target for the diagnosis and treatment of diabetes, and alleviating endoplasmic reticulum stress and improving insulin synthesis and secretion capacity by overexpressing Mettl3.